- Home
- WLK vs JAZZ Comparison
WLK vs JAZZ Comparison
Compare WLK & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLK
- JAZZ
- Stock Information
- Founded
- WLK 1986
- JAZZ 2003
- Country
- WLK United States
- JAZZ Ireland
- Employees
- WLK N/A
- JAZZ N/A
- Industry
- WLK Major Chemicals
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- WLK Industrials
- JAZZ Health Care
- Exchange
- WLK Nasdaq
- JAZZ Nasdaq
- Market Cap
- WLK 7.5B
- JAZZ 8.6B
- IPO Year
- WLK 2004
- JAZZ 2007
- Fundamental
- Price
- WLK $59.05
- JAZZ $177.10
- Analyst Decision
- WLK Buy
- JAZZ Strong Buy
- Analyst Count
- WLK 15
- JAZZ 15
- Target Price
- WLK $88.00
- JAZZ $193.80
- AVG Volume (30 Days)
- WLK 1.4M
- JAZZ 1.4M
- Earning Date
- WLK 10-30-2025
- JAZZ 11-05-2025
- Dividend Yield
- WLK 3.59%
- JAZZ N/A
- EPS Growth
- WLK N/A
- JAZZ N/A
- EPS
- WLK N/A
- JAZZ N/A
- Revenue
- WLK $11,480,000,000.00
- JAZZ $4,157,832,999.00
- Revenue This Year
- WLK N/A
- JAZZ $5.80
- Revenue Next Year
- WLK $3.14
- JAZZ $6.06
- P/E Ratio
- WLK N/A
- JAZZ N/A
- Revenue Growth
- WLK N/A
- JAZZ 4.14
- 52 Week Low
- WLK $56.33
- JAZZ $95.49
- 52 Week High
- WLK $133.51
- JAZZ $182.99
- Technical
- Relative Strength Index (RSI)
- WLK 31.63
- JAZZ 79.33
- Support Level
- WLK $56.33
- JAZZ $128.80
- Resistance Level
- WLK $65.68
- JAZZ $182.99
- Average True Range (ATR)
- WLK 2.47
- JAZZ 6.24
- MACD
- WLK -0.43
- JAZZ 4.45
- Stochastic Oscillator
- WLK 23.44
- JAZZ 89.21
About WLK Westlake Corporation
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.